{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T21:46:13Z","timestamp":1747259173339,"version":"3.37.3"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T00:00:00Z","timestamp":1559260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T00:00:00Z","timestamp":1559260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s00415-019-09397-8","type":"journal-article","created":{"date-parts":[[2019,5,31]],"date-time":"2019-05-31T13:02:32Z","timestamp":1559307752000},"page":"2208-2215","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Lower risk of multiple sclerosis in patients with chronic hepatitis C: a nationwide population-based registry study"],"prefix":"10.1007","volume":"266","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7810-3005","authenticated-orcid":false,"given":"Jonas","family":"S\u00f6derholm","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aylin","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0663-2220","authenticated-orcid":false,"given":"Anders","family":"Svenningsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"B\u00fcsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rune","family":"Wejst\u00e5l","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alma","family":"Brolund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"K\u00f6vamees","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matti","family":"S\u00e4llberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7995-3626","authenticated-orcid":false,"given":"Martin","family":"Lagging","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magnus","family":"Gissl\u00e9n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,5,31]]},"reference":[{"issue":"2","key":"9397_CR1","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1056\/NEJMra1401483","volume":"378","author":"DS Reich","year":"2018","unstructured":"Reich DS, Lucchinetti CF, Calabresi PA (2018) Multiple sclerosis. Longo DL, editor. N Engl J Med 378(2):169\u2013180","journal-title":"N Engl J Med"},{"issue":"5","key":"9397_CR2","doi-asserted-by":"publisher","first-page":"528","DOI":"10.2174\/187152712801661220","volume":"11","author":"J Oskari Virtanen","year":"2012","unstructured":"Oskari Virtanen J, Jacobson S (2012) Viruses and multiple sclerosis. CNS Neurol Disord-Drug Targets Former Curr Drug Targets-CNS Neurol Disord 11(5):528\u2013544","journal-title":"CNS Neurol Disord-Drug Targets Former Curr Drug Targets-CNS Neurol Disord"},{"issue":"1","key":"9397_CR3","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1136\/jnnp-2014-307932","volume":"86","author":"J Gold","year":"2015","unstructured":"Gold J, Goldacre R, Maruszak H, Giovannoni G, Yeates D, Goldacre M (2015) HIV and lower risk of multiple sclerosis: beginning to unravel a mystery using a record-linked database study. J Neurol Neurosurg Psychiatry. 86(1):9\u201312","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"2","key":"9397_CR4","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1097\/EDE.0b013e318281e48a","volume":"24","author":"BA Nex\u00f8","year":"2013","unstructured":"Nex\u00f8 BA, Pedersen L, S\u00f8rensen HT, Koch-Henriksen N (2013) Treatment of HIV and Risk of multiple sclerosis. Epidemiology 24(2):331","journal-title":"Epidemiology"},{"issue":"2","key":"9397_CR5","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1177\/1352458513494489","volume":"20","author":"E Sundqvist","year":"2014","unstructured":"Sundqvist E, Bergstr\u00f6m T, Daialhosein H et al (2014) Cytomegalovirus seropositivity is negatively associated with multiple sclerosis. Mult Scler J 20(2):165\u2013173","journal-title":"Mult Scler J"},{"issue":"3","key":"9397_CR6","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/0168-8278(92)90073-X","volume":"15","author":"AL Zignego","year":"1992","unstructured":"Zignego AL, Macchia D, Monti M et al (1992) Infection of peripheral mononuclear blood cells by hepatitis C virus. J Hepatol 15(3):382\u2013386","journal-title":"J Hepatol"},{"issue":"3","key":"9397_CR7","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1002\/hep.20087","volume":"39","author":"D Ducoulombier","year":"2004","unstructured":"Ducoulombier D, Roque-Afonso A-M, Liberto GD et al (2004) Frequent compartmentalization of hepatitis C virus variants in circulating B cells and monocytes. Hepatology 39(3):817\u2013825","journal-title":"Hepatology"},{"key":"9397_CR8","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/871401","volume":"2012","author":"T Himoto","year":"2012","unstructured":"Himoto T, Masaki T (2012) Extrahepatic manifestations and autoantibodies in patients with hepatitis C virus infection. Clin Dev Immunol 2012:871401","journal-title":"Clin Dev Immunol"},{"issue":"5","key":"9397_CR9","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2174\/1871528113666140908113841","volume":"13","author":"S Mariotto","year":"2014","unstructured":"Mariotto S, Ferrari S, Monaco S (2014) HCV-related central and peripheral nervous system demyelinating disorders. Inflamm Allergy Drug Targets 13(5):299","journal-title":"Inflamm Allergy Drug Targets"},{"issue":"1","key":"9397_CR10","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.autrev.2008.07.027","volume":"8","author":"M Alpa","year":"2008","unstructured":"Alpa M, Ferrero B, Cavallo R et al (2008) Anti-neuronal antibodies in patients with HCV-related mixed cryoglobulinemia. Autoimmun Rev 8(1):56\u201358","journal-title":"Autoimmun Rev"},{"issue":"11","key":"9397_CR11","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1212\/WNL.0b013e318249f6f0","volume":"78","author":"G Disanto","year":"2012","unstructured":"Disanto G, Morahan JM, Barnett MH, Giovannoni G, Ramagopalan SV (2012) The evidence for a role of B cells in multiple sclerosis. Neurology 78(11):823\u2013832","journal-title":"Neurology"},{"issue":"4","key":"9397_CR12","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1080\/14737175.2017.1245616","volume":"17","author":"IM Torres","year":"2017","unstructured":"Torres IM, Garc\u00eda-Merino A (2017) Anti-CD20 monoclonal antibodies in multiple sclerosis. Expert Rev Neurother 17(4):359\u2013371","journal-title":"Expert Rev Neurother"},{"issue":"1","key":"9397_CR13","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/0022-510X(93)90048-4","volume":"114","author":"IL Simone","year":"1993","unstructured":"Simone IL, Annunziata P, Maimone D, Liguori M, Leante R, Livrea P (1993) Serum and CSF anti-GM1 antibodies in patients with Guillain\u2013Barr\u00e9 syndrome and chronic inflammatory demyelinating polyneuropathy. J Neurol Sci 114(1):49\u201355","journal-title":"J Neurol Sci"},{"issue":"2\u20133","key":"9397_CR14","first-page":"99","volume":"93","author":"N Acarin","year":"1996","unstructured":"Acarin N, Rio J, Fernandez AL et al (1996) Different antiganglioside antibody pattern between relapsing-remitting and progressive multiple sclerosis. Acta Neurol Scand 93(2\u20133):99\u2013103","journal-title":"Acta Neurol Scand"},{"issue":"3","key":"9397_CR15","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1089\/jir.2007.0049","volume":"28","author":"G Fortunato","year":"2008","unstructured":"Fortunato G, Calcagno G, Bresciamorra V et al (2008) Multiple sclerosis and hepatitis C virus infection are associated with single nucleotide polymorphisms in interferon pathway genes. J Interferon Cytokine Res 28(3):141\u2013152","journal-title":"J Interferon Cytokine Res"},{"issue":"1","key":"9397_CR16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1177\/1756285611425694","volume":"5","author":"DM Wingerchuk","year":"2012","unstructured":"Wingerchuk DM (2012) Smoking: effects on multiple sclerosis susceptibility and disease progression. Ther Adv Neurol Disord 5(1):13\u201322","journal-title":"Ther Adv Neurol Disord"},{"issue":"6","key":"9397_CR17","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1016\/j.amjmed.2018.01.011","volume":"131","author":"RS Kim","year":"2018","unstructured":"Kim RS, Weinberger AH, Chander G, Sulkowski MS, Norton B, Shuter J (2018) Cigarette smoking in persons living with hepatitis C: the National Health and Nutrition Examination Survey (NHANES), 1999\u20132014. Am J Med 131(6):669\u2013675","journal-title":"Am J Med"},{"issue":"1","key":"9397_CR18","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1080\/00365521.2016.1228119","volume":"52","author":"K B\u00fcsch","year":"2017","unstructured":"B\u00fcsch K, Waldenstr\u00f6m J, Lagging M et al (2017) Prevalence and comorbidities of chronic hepatitis C: a nationwide population-based register study in Sweden. Scand J Gastroenterol 52(1):61\u201368","journal-title":"Scand J Gastroenterol"},{"issue":"8","key":"9397_CR19","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1177\/1352458511403794","volume":"17","author":"C Ahlgren","year":"2011","unstructured":"Ahlgren C, Od\u00e9n A, Lycke J (2011) High nationwide prevalence of multiple sclerosis in Sweden. Mult Scler J. 17(8):901\u2013908","journal-title":"Mult Scler J."},{"key":"9397_CR20","unstructured":"Swedish National Board of Health and Welfare (Socialstyrelsen) (2016) Information available on the National Patient Registry. \n                    http:\/\/www.socialstyrelsen.se\/SiteCollectionDocuments\/information-in-the-national-patient-register.pdf\n                    \n                  . Accessed Sept 2018"},{"key":"9397_CR21","unstructured":"Statistics Sweden (2015) Microdata at Statistic Sweden for research purposes. \n                    https:\/\/www.scb.se\/Grupp\/Tjanster\/SCBs-data-for-forskning.pdf\/\n                    \n                  . Accessed Sept 2018"},{"issue":"9","key":"9397_CR22","doi-asserted-by":"publisher","first-page":"e108599","DOI":"10.1371\/journal.pone.0108599","volume":"9","author":"C Ahlgren","year":"2014","unstructured":"Ahlgren C, Od\u00e9n A, Lycke J (2014) High nationwide incidence of multiple sclerosis in Sweden. PLoS ONE 9(9):e108599","journal-title":"PLoS ONE"},{"issue":"17","key":"9397_CR23","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1212\/WNL.0b013e3181dad57e","volume":"74","author":"KC Simon","year":"2010","unstructured":"Simon KC, van der Mei IAF, Munger KL et al (2010) Combined effects of smoking, anti-EBNA antibodies, and HLA-DRB1*1501 on multiple sclerosis risk. Neurology 74(17):1365\u20131371","journal-title":"Neurology"},{"issue":"21","key":"9397_CR24","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1212\/WNL.0b013e3182752ea8","volume":"79","author":"J Salzer","year":"2012","unstructured":"Salzer J, Hallmans G, Nystr\u00f6m M, Stenlund H, Wadell G, Sundstr\u00f6m P (2012) Vitamin D as a protective factor in multiple sclerosis. Neurology 79(21):2140\u20132145","journal-title":"Neurology"},{"issue":"1","key":"9397_CR25","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1191\/1352458504ms989oa","volume":"10","author":"CH Bombardier","year":"2004","unstructured":"Bombardier CH, Blake KD, Ehde DM, Gibbons LE, Moore D, Kraft GH (2004) Alcohol and drug abuse among persons with multiple sclerosis. Mult Scler J 10(1):35\u201340","journal-title":"Mult Scler J"},{"issue":"1","key":"9397_CR26","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1177\/1352458515579444","volume":"22","author":"K Bj\u00f8rnevik","year":"2016","unstructured":"Bj\u00f8rnevik K, Riise T, Cortese M et al (2016) Level of education and multiple sclerosis risk after adjustment for known risk factors: the EnvIMS study. Mult Scler Houndmills Basingstoke Engl 22(1):104\u2013111","journal-title":"Mult Scler Houndmills Basingstoke Engl"},{"issue":"2","key":"9397_CR27","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1177\/1352458516646863","volume":"23","author":"K Bj\u00f8rnevik","year":"2017","unstructured":"Bj\u00f8rnevik K, Riise T, Benjaminsen E et al (2017) Level of education and multiple sclerosis risk over a 50-year period: registry-based sibling study. Mult Scler Houndmills Basingstoke Engl 23(2):213\u2013219","journal-title":"Mult Scler Houndmills Basingstoke Engl"},{"issue":"suppl 3","key":"9397_CR28","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.1093\/infdis\/jiu057","volume":"209","author":"R Baden","year":"2014","unstructured":"Baden R, Rockstroh JK, Buti M (2014) Natural history and management of hepatitis C: does sex play a role? J Infect Dis 209(suppl 3):S81\u2013S85","journal-title":"J Infect Dis"},{"issue":"3","key":"9397_CR29","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1159\/000369973","volume":"7","author":"S Mihm","year":"2015","unstructured":"Mihm S (2015) Activation of type I and type III interferons in chronic hepatitis C. J Innate Immun 7(3):251\u2013259","journal-title":"J Innate Immun"},{"key":"9397_CR30","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3389\/fimmu.2013.00281","volume":"4","author":"AT Reder","year":"2013","unstructured":"Reder AT, Feng X (2013) Aberrant type I interferon regulation in autoimmunity: opposite directions in MS and SLE, shaped by evolution and body ecology. Front Immunol 4:281","journal-title":"Front Immunol"},{"issue":"2","key":"9397_CR31","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/path.2276","volume":"214","author":"V Appay","year":"2008","unstructured":"Appay V, Sauce D (2008) Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol 214(2):231\u2013241","journal-title":"J Pathol"},{"issue":"2","key":"9397_CR32","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1089\/vim.2006.0060","volume":"20","author":"L Ksiaa","year":"2007","unstructured":"Ksiaa L, Ayed-Jendoubi S, Sfar I et al (2007) Clearance and persistence of hepatitis C virus in a tunisian population: association with HLA class I and class II. Viral Immunol 20(2):312\u2013319","journal-title":"Viral Immunol"},{"issue":"1","key":"9397_CR33","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1002\/hep.20261","volume":"40","author":"SM McKiernan","year":"2004","unstructured":"McKiernan SM, Hagan R, Curry M et al (2004) Distinct MHC class I and II alleles are associated with hepatitis C viral clearance, originating from a single source. Hepatology 40(1):108\u2013114","journal-title":"Hepatology"},{"key":"9397_CR34","doi-asserted-by":"publisher","first-page":"31485","DOI":"10.1038\/srep31485","volume":"6","author":"J Huang","year":"2016","unstructured":"Huang J, Huang K, Xu R et al (2016) The associations of HLA-A*02:01 and DRB1*11:01 with hepatitis C virus spontaneous clearance are independent of IL28B in the Chinese population. Sci Rep 6:31485","journal-title":"Sci Rep"},{"issue":"4","key":"9397_CR35","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1046\/j.1365-2362.1999.00464.x","volume":"29","author":"M Lechmann","year":"1999","unstructured":"Lechmann M, Schneider EM, Giers G et al (1999) Increased frequency of the HLA-DR15 (B1*15011) allele in German patients with self-limited hepatitis C virus infection. Eur J Clin Invest 29(4):337\u2013343","journal-title":"Eur J Clin Invest"},{"issue":"1","key":"9397_CR36","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jns.2014.07.013","volume":"345","author":"R Abolfazli","year":"2014","unstructured":"Abolfazli R, Samadzadeh S, Sabokbar T et al (2014) Relationship between HLA-DRB1* 11\/15 genotype and susceptibility to multiple sclerosis in Iran. J Neurol Sci 345(1):92\u201396","journal-title":"J Neurol Sci"},{"issue":"3","key":"9397_CR37","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1111\/j.1365-3083.2011.02568.x","volume":"74","author":"LOF Cangussu","year":"2011","unstructured":"Cangussu LOF, Teixeira R, Campos EF et al (2011) HLA class II alleles and chronic hepatitis C virus infection. Scand J Immunol 74(3):282\u2013287","journal-title":"Scand J Immunol"},{"key":"9397_CR38","unstructured":"Dean L (2012) Sofosbuvir Therapy and IFNL4 Genotype. In: Pratt V, McLeod H, Rubinstein W, Dean L, Kattman B, Malheiro A (eds). Med Genet Summ [Internet]. Bethesda (MD): National Center for Biotechnology Information (US). \n                    https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK409960\/\n                    \n                  . Accessed 7 Nov 2018"},{"issue":"7262","key":"9397_CR39","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nature08309","volume":"461","author":"D Ge","year":"2009","unstructured":"Ge D, Fellay J, Thompson AJ et al (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461(7262):399\u2013401","journal-title":"Nature"},{"issue":"7265","key":"9397_CR40","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/nature08463","volume":"461","author":"DL Thomas","year":"2009","unstructured":"Thomas DL, Thio CL, Martin MP et al (2009) Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461(7265):798\u2013801","journal-title":"Nature"},{"issue":"1\u20132","key":"9397_CR41","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jneuroim.2011.08.004","volume":"239","author":"S Malhotra","year":"2011","unstructured":"Malhotra S, Morcillo-Su\u00e1rez C, Brassat D et al (2011) IL28B polymorphisms are not associated with the response to interferon-beta in multiple sclerosis. J Neuroimmunol 239(1\u20132):101\u2013104","journal-title":"J Neuroimmunol"},{"issue":"21","key":"9397_CR42","first-page":"18882","volume":"13","author":"A Duberg","year":"2008","unstructured":"Duberg A, Janzon R, B\u00e4ck E, Ekdahl K, Blaxhult A (2008) The epidemiology of hepatitis C virus infection in Sweden. Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull 13(21):18882","journal-title":"Euro Surveill Bull Eur Sur Mal Transm Eur Commun Dis Bull"},{"issue":"4","key":"9397_CR43","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1097\/CEJ.0b013e32834572fa","volume":"20","author":"JN Hofmann","year":"2011","unstructured":"Hofmann JN, T\u00f6rner A, Chow W-H, Ye W, Purdue MP, Duberg A-S (2011) Risk of kidney cancer and chronic kidney disease in relation to hepatitis C virus infection: a nationwide register-based cohort study in Sweden. Eur J Cancer Prev 20(4):326\u2013330","journal-title":"Eur J Cancer Prev"},{"issue":"12","key":"9397_CR44","doi-asserted-by":"publisher","first-page":"1452","DOI":"10.1111\/jvh.12969","volume":"25","author":"M K\u00e5berg","year":"2018","unstructured":"K\u00e5berg M, Nav\u00e9r G, Hammarberg A, Weiland O (2018) Incidence and spontaneous clearance of hepatitis C virus (HCV) in people who inject drugs at the Stockholm Needle Exchange\u2014importance for HCV elimination. J Viral Hepat 25(12):1452\u20131461","journal-title":"J Viral Hepat"},{"issue":"6","key":"9397_CR45","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1111\/ane.12408","volume":"132","author":"A Svenningsson","year":"2015","unstructured":"Svenningsson A, Salzer J, V\u00e5gberg M, Sundstr\u00f6m P, Svenningsson A (2015) Increasing prevalence of multiple sclerosis in V\u00e4sterbotten County of Sweden. Acta Neurol Scand 132(6):389\u2013394","journal-title":"Acta Neurol Scand"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-019-09397-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-019-09397-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-019-09397-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,29]],"date-time":"2020-05-29T23:27:48Z","timestamp":1590794868000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-019-09397-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,31]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["9397"],"URL":"https:\/\/doi.org\/10.1007\/s00415-019-09397-8","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"type":"print","value":"0340-5354"},{"type":"electronic","value":"1432-1459"}],"subject":[],"published":{"date-parts":[[2019,5,31]]},"assertion":[{"value":"13 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 May 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"ML is a consultant for AbbVie, BMS, Gilead, Medivir, and MSD\/Merck, and is a member of the speakers\u2019 bureaus for AbbVie, BMS, Gilead, Medivir, and MSD\/Merck. MG has received research grants from Gilead Sciences and received honoraria as speaker and\/or scientific advisor from AbbVie, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline\/ViiV, Janssen-Cilag, and MSD. MS is founder and owner of Svenska Vaccinfabriken AB. RW has received consultant fees from AbbVie for medical advisory board and teaching. AY has received lecture fees from Gilead, Janssen, and AbbVie. AS have nothing to disclose. JS, JK, and KB are employees of AbbVie and may hold AbbVie stocks or stock options. AB is a former employee of AbbVie and may hold AbbVie stocks or stock options.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study was approved by the Stockholm Regional Ethics Committee at Karolinska Institutet (Sweden) and has been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standard"}}]}}